Trials / Withdrawn
WithdrawnNCT01705379
Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects 2 Years of Age and Older
A Multicenter, Single Arm, Post Marketing Surveillance Study to Monitor the Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) Administered According to the Prescribing Information to Healthy Subjects 2 Years of Age and Older in the Philippines
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Novartis Vaccines · Industry
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- Accepted
Summary
A multicenter, single arm, postmarketing surveillance study. This study is a postlicensure requirement of the Philippine Food and Drug Administration (FDA) to provide continued safety evaluation of MenACWY-CRM in Philippine individuals 2 years of age and older, receiving MenACWY-CRM vaccination according to routine clinical practice and prescribing information.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Novartis Meningococcal ACWY Conjugate Vaccine | Immunization |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2016-04-01
- Completion
- 2016-04-01
- First posted
- 2012-10-12
- Last updated
- 2016-12-01
Source: ClinicalTrials.gov record NCT01705379. Inclusion in this directory is not an endorsement.